Studies with GRK2 inhibition coupled with a β-blocker in HF as shown in most models to be additive or even synergistic, also supporting non-β-AR mechanisms involved in the therapeutic responses to GRK2 inhibitors (Sato et al., 2015). The gene discussed is ADRB2; the disease is hydrops fetalis.